Navigation Links
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Date:12/3/2007

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for SGX523. This compound is an internally developed, orally-bioavailable, small molecule inhibitor of the cMET receptor tyrosine kinase. The Company expects to begin Phase I clinical trials of SGX523 for solid tumor cancer patients in early 2008.

"This IND submission is one quarter earlier than originally anticipated and represents a significant achievement for our organization," said Mike Grey, President and Chief Executive Officer of SGX Pharmaceuticals. "Submission of the SGX523 IND package less than ten months after the compound's nomination as a formal development candidate speaks highly of the effectiveness of our research and development capabilities. We look forward to capitalizing on this positive momentum and initiating clinical studies in solid tumor cancer patients following FDA review of our submission."

About SGX523 and cMET

SGX523 has shown significant selectivity for the cMET receptor tyrosine kinase over more than 200 protein kinases and has demonstrated both potent in vitro blockade of the activity of this cancer target and in vivo activity against human cancer cells that depend on cMET for their uncontrolled growth and proliferation. The cMET receptor tyrosine kinase has been implicated in a wide range of cancers, including both solid and blood tumors. cMET has been extensively studied in both the laboratory environment and the clinic, with increasing data suggesting that uncontrolled stimulation of cMET plays a key role in a variety of effects associated with cancer, inc
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... WI (PRWEB) October 25, 2014 ... tax-advantaged medical and other benefits account management services, ... to help employers save on taxes, reduce administrative ... Suites provide tax savings and the efficient handling ... pick the Suite that best meets their goals ...
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
(Date:10/25/2014)... News) -- October,s shorter, darker days can trigger a ... to an expert. People affected by seasonal ... lack motivation and even have trouble getting out of ... said Dr. Angelos Halaris, a professor in the department ... Stitch School of Medicine. "Seasonal affective disorder should ...
(Date:10/22/2014)... MI (PRWEB) October 22, 2014 ... Schools of Allied Health Professions (ASAHP) Conference on October ... and CEO will participate in a panel discussion on ... Practice. , Isabel Healthcare provides a diagnostic decision support ... improving the diagnosis skills of students and clinical learners. ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... manufactured by Merck & Co would result in an increased ... taking the drug. // Statistics show that about 60 patients ... six to 13 days after they first started taking Vioxx. ... Journal. It was contrary to what Merck had previously told ...
... of the Food and Drug Administration has been subjected ... // ,Attorney Barbara Van Gelder has mentioned ... of Lester Crawford. She is believed to have ... Thursday, that she would instruct him to invoke his ...
... and polio immunization campaign commenced with a bit of ... with their children to avail immunization, // and this ... Infact, the stock of vaccines started getting depleted by ... of the vaccination drive. ,Assistant Minister for Medical ...
... hypothermia to help patients with severe heart disease or ... Dalton Dietrich and his colleagues noticed// that the rats ... stroke, but had different responses. ,"We ... temperatures in the rats' brains they found that rates ...
... University Medical School in Melbourne, Australia, it was found ... than a very low-calorie diet.// The surgical procedure consists ... stomach to create a feeling of fullness in patients ... those who have serious medical conditions, such as type ...
... A study conducted by a Brown Medical School professor ... say that postpartum depression is linked to fussy babies.//, ... clinical professor of paediatrics at Brown Medical School and ... Other members include Rhode Island Department of Health's Division ...
Cached Medicine News:
(Date:10/25/2014)... , October 24, 2014 ... ) has announced the addition of the  ... 2014"  report to their offering.  ... and Chinese Acne Medication Industry Report 2014 ... the current state of the global acne ...
(Date:10/25/2014)... Oct. 24, 2014  As the building blocks ... company access to diverse skill sets and expertise, ... clock business hours for efficiency. However, effectively managing ... According to recent research, more than ... seeing a project not move forward due to ...
(Date:10/22/2014)... 22, 2014  Rescheduling of hydrocodone combination products ... pain market, according to a new primary market ... providing market research and consultation exclusively in the ... http://photos.prnewswire.com/prnh/20141021/153440 In August, ... combination products from Schedule III to Schedule II ...
Breaking Medicine Technology:Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... 2011 The GlaxoSmithKline 15th Annual IMPACT Awards target ... underserved. Up to ten organizations in the Pennsylvania Counties ... Philadelphia and in the City of Camden, New Jersey, ... are bestowed upon winning organizations for success and achievements ...
... American Scientific Resources, Inc. (Pink Sheets: ... non-contact thermometer. Updating the packaging to a brighter cleaner ... thermometer. "We made the changes to distance ... foreign model previously sold by American Scientific Resources; to ...
Cached Medicine Technology:GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits 2American Scientific Resources Rebrands Non-Contact Thermometer for Mass Market Consumer Appeal 2
... Used to establish and maintain ... ureteral segment promotes patency and allows ... subsides. Supplied sterile in peel-open packages. ... evaluation is advised; stent must not ...
... drainage following open renal or bladder ... provide enhanced drainage and promote catheter ... for enhanced patient comfort and provides ... Supplied sterile in peel-open packages. Intended ...
... Used for percutaneous ... catheter in the renal ... Supplied sterile in peel-open ... use. CAUTION: Periodic evaluation ...
... contains primers and a FAM-labeled probe targeting the ... Parvo B19 ASR contains primers and a Texas ... ASR requires an instrument that can detect FAM ... The Cepheid Analyte Specific Reagent* (ASR) program is ...
Medicine Products: